Medesis Pharma S.A.

Legal Proceedings Report • Oct 3, 2023

PRESS RELEASE

MEDESIS PHARMA RECEIVES APPROVAL FROM THE MONTPELLIER COMMERCIAL COURT TO OPEN A SAFEGUARD PROCEDURE

Monteller, October 3, 2023 at 0:00pm CET – MEDESIS PHARMA biotehinology
company developing candidates based on its propries anninininian in the miniminal in the mark
has

li is remided hat being MEDSity and Definace, with led the Monteller Commercial
Seen eleing of Marcon MEDS More on the Monteller Comment
Desements with Minange, Medels manner

n a rasmily o natumiy santara agostina da salam anterned.
Samaria Currente ages no opini al research procempira. Mar Monollia
Samaria Cur Thisana dell'in differend procession

28 historical Medesis Phama benontrated their confidence and suport by commiting
to a current account he architely do,00 euros to ensure in commiting in commission in annin

Medss Pharma confirms that in Alzheiner's disease is coninuing, wih all 68
painte spected by the end of Order Preliminer in all 68 minutes on the minutes on bleat play black.

The search for pharmaceutical partners for parnerships and/or licenses continues in collaboration with Alzheimer's disease clinical study.

Medesis Pharma will continue to keep the market informed of any new developments.

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated affer a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 12 patent families and 72 patents, the result of 20 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information: www.medesispharma.com

MEDESIS PHARMA Jean Claude Maurel Tel: +33 4 67 03 03 96 contact@medesispharma.com

CAI YPTUS Marie Calleux Tel : +33 1 53 65 68 66 medesispharma@calyptus.net